Quest Diagnostics was founded in 1967 by Paul A. Brown as Metropolitan Pathology Laboratory, Inc.
The company grew by acquisitions, most notably MedPlus in 2001, Unilab Corporation in 2003, LabOne in 2005, and Celera Corporation in 2011.
Today Quest Diagnostics is the world’s leading clinical lab with the performance of diagnostics of 147 million specimens each year.
Quest Diagnostics performs routine tests such as cholesterol, Pap smears, and HIV screenings, as well as esoteric screenings such as genetic screening, and anatomic pathology testing such as tissue biopsies for cancer testing.
The company has more than 2,000 patient service centers where samples are collected.
In November 2018, Quest launched QuestDirect, a consumer-initiated testing service that allows patients to order health and wellness lab testing from home,
In March 2020, the company launched a Covid-19 testing service.
Quest Diagnostics trades publicly on the New York Stock Exchange under the ticker symbol DGX, is a member of the S&P 500, is #303 in the Fortune 500, has 41,000 employees, and had $7.73 billion in revenue in 2019.
Quest Diagnostics maintains a corporate office in Secaucus, New Jersey.
Quest Diagnostics was founded in 1967 by Paul A. Brown as Metropolitan Pathology Laboratory, Inc.
The company grew by acquisitions, most notably MedPlus in 2001, Unilab Corporation in 2003, LabOne in 2005, and Celera Corporation in 2011.
History
Today Quest Diagnostics is the world’s leading clinical lab with the performance of diagnostics of 147 million specimens each year.
Quest Diagnostics performs routine tests such as cholesterol, Pap smears, and HIV screenings, as well as esoteric screenings such as genetic screening, and anatomic pathology testing such as tissue biopsies for cancer testing.
The company has more than 2,000 patient service centers where samples are collected.
In November 2018, Quest launched QuestDirect, a consumer-initiated testing service that allows patients to order health and wellness lab testing from home,
In March 2020, the company launched a Covid-19 testing service.
Quest Diagnostics trades publicly on the New York Stock Exchange under the ticker symbol DGX, is a member of the S&P 500, is #303 in the Fortune 500, has 41,000 employees, and had $7.73 billion in revenue in 2019.
Quest Diagnostics maintains a corporate office in Secaucus, New Jersey.
